Intercept Pharmaceuticals, Inc.
ICPTNASDAQHealthcare
$19.00
+$0.04(+0.21%)
Market Cap$794694000
P/E Ratio—
52W High$21.86
52W Low$8.82
Intercept Pharmaceuticals, Inc. (ICPT) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ICPT · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2022-12 | 2021-12 | 2020-12 | 2019-12 | 2018-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.29B | $0.36B | $0.31B | $0.25B | $0.18B |
| Cost of Revenue | $0.00B | $0.00B | $0.01B | $0.00B | $0.00B |
| Gross Profit | $0.28B | $0.36B | $0.31B | $0.25B | $0.18B |
| Gross Margin %(computed) | 99.66% | 99.15% | 98.30% | 98.33% | 98.60% |
| Operating Expenses | |||||
| R&D Expenses | $0.18B | $0.19B | $0.19B | $0.24B | $0.21B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.26B |
| Total Operating Expenses | $0.35B | $0.42B | $0.52B | $0.56B | $0.46B |
| Operating Income | ($0.07B) | ($0.06B) | ($0.22B) | ($0.31B) | ($0.29B) |
| Operating Margin %(computed) | -23.88% | -15.34% | -69.27% | -123.98% | -158.78% |
| Interest Income | $0.02B | $0.05B | $0.04B | $0.03B | $0.00B |
| Interest Expense | $0.02B | $0.05B | $0.05B | $0.04B | $0.03B |
| Income Before Tax | ($0.17B) | ($0.09B) | ($0.27B) | ($0.34B) | ($0.31B) |
| Income Tax Expense | ($0.29B) | $0.05B | $0.05B | $0.05B | $0.00B |
| Net Income | $0.12B | ($0.15B) | ($0.32B) | ($0.39B) | ($0.31B) |
| Net Margin %(computed) | 40.31% | -39.90% | -103.69% | -155.18% | -171.99% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $3.41 | $-4.55 | $-9.83 | $-12.35 | $-10.86 |
| Wtd Avg Shares | 0.03B | 0.03B | 0.03B | 0.03B | 0.03B |
| EBITDA | ($0.06B) | ($0.03B) | ($0.21B) | ($0.29B) | ($0.28B) |
| EBITDA Margin %(computed) | -21.59% | -9.59% | -67.86% | -116.92% | -155.01% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · B
Explore more Intercept Pharmaceuticals, Inc. data
About Intercept Pharmaceuticals, Inc. (ICPT) Income Statement
Intercept Pharmaceuticals, Inc. (ICPT) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2022, ICPT reported revenue of $0.29B, gross profit of $0.28B (gross margin 99.66%), and net income of $0.12B — a net profit margin of 40.31%.
Frequently asked questions
ICPT · 4 questionsIntercept Pharmaceuticals, Inc. (ICPT) reported revenue of $0.29B for 2022, down 21.4% year-over-year.
ICPT revenueICPT salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09